Product Pathways - Growth Factors/Cytokines
Human TL1A/TNFSF15 (hTL1A) #11946
|11946LC||50 µg (With Carrier)||---||In Stock||---|
|11946LF||50 µg (Carrier Free)||---||In Stock||---|
|11946SC||10 µg (With Carrier)||---||In Stock||---|
|11946SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant Human TL1A Leu72-Leu251 (Accession #NP_095150) was expressed in E.coli at Cell Signaling Technology.
Recombinant hTL1A has a calculated MW of 20,0473. DTT-reduced protein migrates as a 21 kDa polypeptide. The nonreduced protein migrates as a 21 kDa monomer and 38 kDa cystine-linked homodimer. The expected amino terminus of recombinant hTL1A was verified by amino acid sequencing.
>95% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hTL1A. All lots are greater than 95% pure.
The bioactivity of hTL1A was determined in a TF-1 cell viability assay. The ED50 of each lot is between 2-15 ng/ml.
The purity of recombinant hTL1A was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant hTL1A and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg hTL1A.
With carrier: Lyophilized from a 0.22 μm filtered solution of hTL1A in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg hTL1A. Carrier free: Lyophilized from a 0.22 μm filtered solution of hTL1A in 20 mM Tris, pH 7.2.
TL1A (TNFSF15), a member of the TNF superfamily of proteins, is a splice variant of the TL1/VEGI gene (1). Endothelial cells, monocytes, macrophages, and dendritic cells express TL1A, which is upregulated by proinflammatory cytokines, microorganisms, and AMPK activation (1-4). TL1A activates the NF-κB and JNK pathways through its receptor, DR3 (1,5). TL1A may function as a costimulatory signal for T cell activation, specifically regulating Th17 cell development and proliferation (1,2,6). Mouse models suggest a role for TL1A as a driver for the inflammation and pathogenesis associated with inflammatory bowel disease (7,8).
- Migone, T.S. et al. (2002) Immunity 16, 479-92.
- Jones, G.W. et al. (2011) FASEB J 25, 409-19.
- Zhou, J. et al. (2011) Oncogene 30, 1892-900.
- Shih, D.Q. et al. (2009) Eur J Immunol 39, 3239-50.
- Haridas, V. et al. (1999) Oncogene 18, 6496-504.
- Pappu, B.P. et al. (2008) J Exp Med 205, 1049-62.
- Meylan, F. et al. (2011) Mucosal Immunol 4, 172-85.
- Taraban, V.Y. et al. (2011) Mucosal Immunol 4, 186-96.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.